• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [271 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: the experience of people living with neurocognitive disorders in Quebec]
2024 Basque Office for Health Technology Assessment (OSTEBA) [Exoskeletons for the functional recovery of walking ability in patients with central nervous system disorders such as multiple sclerosis, stroke, and traumatic spinal injury]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: expressing wishes regarding goals of care and the decision about cardiopulmonary resuscitation]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: a brief overview of indicators for care and service transitions of community-dwelling seniors with major neurocognitive disorder (MNCD) in Quebec]
2024 NIHR Health Technology Assessment programme A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding universal screening for congenital cytomegalovirus (CMV) infection to Québec newborn screening program]
2024 National Institute for Health and Care Excellence (NICE) Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal). NICE technology appraisal guidance 960
2024 NIHR Health Services and Delivery Research programme Improving support and planning ahead for older people with learning disabilities and family carers: a mixed-methods study
2024 Institute for Clinical Effectiveness and Health Policy (IECS) [Extracorporeal membrane oxygenation for acute respiratory distress syndrome and lung transplantation in adults]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding a genetic variant of mucolipidosis type II to the carrier testing offer for people from the Saguenay-Lac-Saint-Jean, Charlevoix, and Haute-Côte-Nord regions]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding two genetic variants of Zellweger spectrum disorder to the carrier testing offer for people from the Saguenay-Lac-Saint-Jean, Charlevoix, and Haute-Côte-Nord regions]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of intensive behavioural intervention (EIBI) for preschool-age autistic children in Québec]
2024 Institute for Clinical Effectiveness and Health Policy (IECS) [Artificial urinary sphincter in pediatric patients]
2024 NIHR Health Technology Assessment programme The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024 Health Sciences Institute in Aragon (IACS) [Portable external trigeminal nerve stimulator (eTNS) device for the treatment of migraine headaches]
2024 Swiss Federal Office of Public Health (FOPH) Trikafta® for the treatment of patients with cystic fibrosis: an exploratory economic evaluation
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of placental growth factor (PlGF) testing in suspected preeclampsia]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: care management for youth under 18 with attention deficit hyperactivity disorder (ADHD)]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: psychosocial interventions in youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2024 Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Mechanisms and interventions to prevent intrusive wandering by residents with neurocognitive disorders in long-term care facilities]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: continuum of care and services for individuals with a traumatic spinal cord injury in Québec - characteristics, care pathways and clinical outcomes for adults from 2014 to 2020]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: cryotherapy for the prevention of taxane-induced peripheral neuropathy]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for glutaric acidemia type 1 (GA1)]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for for long-chain acyl-CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (TFPD)]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevant practices for promoting hearing health in long-term residential care settings]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in neurology]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in pediatrics]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in psychiatry]
2023 NIHR Health Technology Assessment programme Antidepressants in pregnancy: applying causal epidemiological methods to understand service-use outcomes in women and long-term neurodevelopmental outcomes in exposed children
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organizational models for the management of spinal cord injuries]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V]
2023 Malaysian Health Technology Assessment (MaHTAS) Nasojejunal tube in upper gastrointestinal conditions
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: principles and criteria guiding the use of parent-child trio genomewide sequencing in constitutional genetics - a report to support the work of the RQDM]
2023 Swiss Federal Office of Public Health (FOPH) Folate tests for suspected folate deficiency
2023 National Institute for Health and Care Excellence (NICE) Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal). NICE technology appraisal guidance 941
2023 Haute Autorite de sante (HAS) [Comparative genomic hybridization array (CGHA) analysis in postnatal context]
2022 Swiss Federal Office of Public Health (FOPH) Levothyroxine for patients diagnosed with subclinical hypothyroidism
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Satralizumab (neuromyelitis optica spectrum disorders, anti-aquaporin-4IgG seropositive, ≥ 12 years)]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: immunoglobulin shortage: alternative treatments to nonspecific human immunoglobulins]
2022 Austrian Institute for Health Technology Assessment (AIHTA) ATMPs and gene therapies in development. Horizon scanning – update 2022
2022 Scottish Health Technologies Group (SHTG) vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2022 WorkSafeBC Intravenous ketamine for PTSD and treatment-resistant depression
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of immunoglobulin in fertility, cardiology and other indications]
2022 WorkSafeBC Functional neurology as treatment for post-traumatic brain injury
2022 WorkSafeBC Percussion therapy for neuropathic pain
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: use of electrodiagnostic testing in the neurological investigation - electromyography and nerve conduction studies]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) - Benefit assessment according to § 35a SGB V]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for argininosuccinic aciduria (ASA)]
2022 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Efficacy and safety of transanal irrigation in adults with bowel dysfunction]
2022 Haute Autorite de sante (HAS) [Transcranial magnetic stimulation (rTMS) in the treatment of adult treatment-resistant depression]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of the SpaceOAR hydrogel rectal spacer during prostate radiotherapy]
2021 Norwegian Institute of Public Health (NIPH) [Intravenous immunoglobulin treatment in children with PANS/PANDAS conditions]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating diagnostic measures in a person with signs and symptoms suggestive of a urinary tract infection (cystitis or pyelonephritis) and initiating first-line pharmacological treatment for cystitis in an adult with functional autonomy decline]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: urinary catheter placement in an adult with functional autonomy decline presenting with symptoms suggestive of acute urinary retention]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of single-photon emission computed tomography with [ 123I]ioflupane (DaTscan) in the diagnostic process for parkinsonian syndromes]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of newborn screening for spinal muscular atrophy]
2021 Swiss Federal Office of Public Health (FOPH) Effectiveness and safety of vitamin B12 tests
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: care pathways leading to the diagnostic assessment of neurodevelopmental disorders in children 0-7 years old]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulins in infectious diseases]
2021 Institute for Clinical Effectiveness and Health Policy (IECS) [Stem cell therapy: clinical applications]
2021 Institute for Clinical Effectiveness and Health Policy (IECS) [Whole-exome sequencing in patients with neurological disorders]
2021 Malaysian Health Technology Assessment (MaHTAS) Driving simulator in healthcare
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Satralizumab (neuromyelitis optica spectrum disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 NIHR Health Technology Assessment programme Medically unexplained symptoms(MUS): primary care intervention
2020 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Efectiveness of Newborn Screening for Inborn Errors of Metabolism by MS/ MS. Update and pilot study assessment: Maple Syrup Urine Disease; Isovaleric Acidaemia; Homocystinuria]
2020 Andalusian Health Technology Assessment Area (AETSA) Efficacy, effectivity and safety of physical therapies for neuromuscular diseases: systematic review
2020 NIHR Health Technology Assessment programme Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation
2020 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: update of the systematic review of the effects of palivizumab prophylaxis on reducing complications associated with respiratory syncytial virus infections in children]
2020 Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: initiating a blood profile after detecting suggestive symptoms and signs of mild or major neurocognitive disorder]
2020 National Committee for Technology Incorporation (CONITEC) [Mirabegron for the treatment of storage dysfunction in patients with neurogenic bladder]
2020 National Committee for Technology Incorporation (CONITEC) [Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2020 Malaysian Health Technology Assessment (MaHTAS) Acupuncture for headache, refractory neuralgia, Bell’s palsy, post-stroke, Guillain barre and transverse myelitis
2020 Adelaide Health Technology Assessment (AHTA) Detection of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibody (MOG) antibodies for diagnosis of neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein antibody-related demyelination (MARD)
2019 Institute for Clinical Effectiveness and Health Policy (IECS) [Quantitative electroencephalography]
2019 The Regional Health Technology Assessment Centre (HTA-centrum) EEG-based neurofeedback as treatment for post-traumatic stress disorder
2018 NIHR Health Technology Assessment programme Pharmacological and non-pharmacological interventions for non-respiratory sleep disturbances in children with neurodevelopmental disorders: a systematic review
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Music therapy in children with developmental disorders]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for patients with diagnosed chronic neuromyelitis, myasthenia gravis and chronic inflammatory demyelinating polyneuropathy]
2018 Agency for Healthcare Research and Quality (AHRQ) Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents
2018 Agency for Healthcare Research and Quality (AHRQ) Noninvasive nonpharmacological treatment for chronic pain: a systematic review
2018 National Institute for Health and Care Excellence (NICE) Peristeen Plus transanal irrigation system for managing bowel dysfunction. NICE medical technologies guidance 36
2017 HAYES, Inc. Hydrogen breath tests for diagnosis of small intestinal bacterial overgrowth in functional bowel disorders
2017 HAYES, Inc. GeneSight Psychotropic (Assurex Health Inc.)
2017 HAYES, Inc. Prometheus IBD sgi Diagnostic (Prometheus Laboratories Inc.)
2017 NIHR Health Technology Assessment programme A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)
2017 HAYES, Inc. Hydrogen breath test in patients with functional bowel disorders and suspected carbohydrate malabsorption
2017 HAYES, Inc. Hydrogen breath tests for diagnosis of small intestinal bacterial overgrowth in functional bowel disorders
2017 HAYES, Inc. Intravenous lidocaine infusion for neuropathic pain: a review of reviews
2017 HAYES, Inc. Open sacroiliac joint fusion for unspecified sacroiliac joint dysfunction
2017 HAYES, Inc. Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies
2017 HAYES, Inc. Wireless capsule systems for diagnosis of gastroparesis and monitoring of gastrointestinal motility
2017 HAYES, Inc. Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients
2017 HAYES, Inc. Transcranial direct current stimulation for depression
2017 Institut national d'excellence en sante et en services sociaux (INESSS) [Report on optimal antipsychotic use and the nonpharmacological management of the behavioural and psychological symptoms of dementia in people with major neurocognitive disorders living in residential and long-term care centers]
2017 Institut national d'excellence en sante et en services sociaux (INESSS) [Report and optimal usage guide: immunoglobulins in neurology]
2017 Institute for Clinical Effectiveness and Health Policy (IECS) [Cerebrospinal fluid neurotransmitter screening in encephalopathies]
2017 Agency for Healthcare Research and Quality (AHRQ) Diagnostic accuracy of screening and treatment of post-acute coronary syndrome depression: a systematic review
2016 NIHR Health Technology Assessment programme Orthotic management of instability of the knee related to neuromuscular and central nervous system disorders: systematic review, qualitative study, survey and costing analysis
2016 Institute for Clinical Effectiveness and Health Policy (IECS) Magnetic resonance spectroscopy and magnetic resonance imaging with tractography for psychiatric disorders